{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:27:38Z","timestamp":1790522858164,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Advicenne"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejps.2017.11.030","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:13:23Z","timestamp":1512519203000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-6623","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Mar\u00e7on","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc-Andr\u00e9","family":"Granier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Jacqmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.11.030_bb0005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2165\/00003088-200241120-00003","article-title":"Ontogeny of hepatic and renal systemic clearance pathways in infants: part I","volume":"41","author":"Alcorn","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/clpt.1981.217","article-title":"Midazolam kinetics","volume":"30","author":"Allonen","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations","volume":"45","author":"Bartelink","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.0306-5251.2001.01521.x","article-title":"The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity","volume":"53","author":"Belle","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00547375","article-title":"Dose dependent pharmacokinetics of midazolam","volume":"29","author":"Bornemann","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.1994.186","article-title":"Population pharmacokinetics of midazolam in neonates","volume":"56","author":"Burtin","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10928-010-9175-z","article-title":"The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects","volume":"38","author":"Chan","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.11.030_bb0040","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2017"},{"key":"10.1016\/j.ejps.2017.11.030_bb0045","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/BF03021583","article-title":"Evidence-based clinical update: does premedication with oral midazolam lead to improved behavioural outcomes in children?","volume":"53","author":"Cox","year":"2006","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.ejps.2017.11.030_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003088-199427060-00004","article-title":"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents","volume":"27","author":"Greiff","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0055","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s11095-017-2193-4","article-title":"A two-way randomized cross-over pharmacokinetic and pharmacodynamic study of an innovative oral solution of midazolam (ADV6209)","volume":"34","author":"Guittet","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.11.030_bb0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2710.2010.01178.x","article-title":"Pharmacokinetics of midazolam tablet in different Chinese ethnic groups","volume":"36","author":"Guo","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0065","first-page":"2220","article-title":"Excretion and metabolism of 14C-midazolam in humans following oral dosing","volume":"31","author":"Heizmann","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2017.11.030_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-2125.2000.00104.x","article-title":"Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects. Brit","volume":"49","author":"Hotz","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0075","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1213\/01.ANE.0000130852.53082.D5","article-title":"Propofol and midazolam inhibit gastric emptying and gastrointestinal transit in mice","volume":"99","author":"Inada","year":"2004","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejps.2017.11.030_bb0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40262-013-0050-0","article-title":"A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults","volume":"52","author":"Ince","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0085","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/bja\/89.3.428","article-title":"Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis","volume":"89","author":"Johnson","year":"2002","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejps.2017.11.030_bb9000","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12078-008-9008-2","article-title":"Masking Bitter Taste by Molecules","volume":"1","author":"Ley","year":"2008","journal-title":"Chemosens. Percept."},{"key":"10.1016\/j.ejps.2017.11.030_bb0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","article-title":"Prediction of drug clearance in children from adults: a comparison of several allometric methods","volume":"61","author":"Mahmood","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0095","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","article-title":"Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings","volume":"53","author":"Mahmood","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijpharm.2009.05.029","article-title":"Development and formulation of a 0.2% oral solution of midazolam containing gamma-cyclodextrin","volume":"379","author":"Mar\u00e7on","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.11.030_bb0110","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.107.015214","article-title":"Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4","volume":"35","author":"Miyagi","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.11.030_bb0115","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0090-9556(25)06755-8","article-title":"Liver volume as a determinant of drug clearance in children and adolescents","volume":"23","author":"Murry","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.11.030_bb0120","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF01061761","article-title":"The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon","volume":"15","author":"Oberle","year":"1987","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2017.11.030_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00679782","article-title":"The pharmacokinetics of midazolam in paediatric patients","volume":"37","author":"Payne","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/00912700122012832","article-title":"The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration","volume":"41","author":"Reed","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0135","first-page":"355","article-title":"Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration","volume":"41","author":"Rey","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0140","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.11.030_bb0145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bcp.13083","article-title":"Comparative performance of oral midazolam clearance and plasma 4\u03b2-hydroxycholesterol to explain interindividual variability in tacrolimus clearance","volume":"82","author":"Vanhove","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb9005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addr.2014.02.012","article-title":"European Formulation Initiative. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients","volume":"73","author":"Walsh","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.11.030_bb0155","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0090-9556(24)15233-6","article-title":"A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration","volume":"27","author":"Wang","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.11.030_bb0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/aps.2015.122","article-title":"Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration","volume":"37","author":"Wang","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2017.11.030_bb0165","first-page":"160","article-title":"Pharmacokinetics of single dose midazolam in children. Abstract","volume":"49","author":"Wells","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.11.030_bb0170","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.11.030_bb0175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2125.2002.01223.x","article-title":"Pharmacokinetics and metabolism of oral midazolam in preterm infants","volume":"53","author":"de Wildt","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.030_bb0180","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/01.ccm.0000084806.15352.da","article-title":"Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients","volume":"31","author":"de Wildt","year":"2003","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejps.2017.11.030_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/ elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.11.030_bb0190","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1124\/dmd.106.011387","article-title":"Epirubicin glucuronidation and UGT2B7 developmental expression","volume":"34","author":"Zaya","year":"2006","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717306590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717306590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:31:42Z","timestamp":1751070702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717306590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"alternative-id":["S0928098717306590"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.11.030","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733014751.793544640","asserted-by":"object"}]},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}